India, July 26 -- Autonomix Medical Inc. (AMIX), a medical device company, on Friday announced preclinical results of a neural sensing platform to facilitate renal denervation and identify changes in renal neural activity.
Renal denervation has been viewed as an effective treatment for resistant hypertension, yet identifying existing renal neural activity during the procedure posed a significant challenge.
The study involved introducing a catheter endovascularly into the renal arteries of an animal model. As neural activity was detected, specific signal patterns were identified. This was followed by the targeted ablation of the nerve ends, consequently leading to attenuated signals, thus completing the renal denervation procedure.
The co...